Circulating ESM-1 (endocan) in the assessment of atrial fibrillation and/or stroke

Patent metadata

Field	Value
Publication number	US-12480959-B2
Application number	US-201916264779-A
Country	US
Kind code	B2
Filing date	Feb 1, 2019
Priority date	Aug 4, 2016
Publication date	Nov 25, 2025
Grant date	Nov 25, 2025

Abstract

Disclosed is a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure is disclosed.

First claim

The invention claimed is:

1 . A method for assessing atrial fibrillation in a human subject with documented atrial fibrillation, comprising the steps of
a) detecting the amount of Endocan (ESM-1) and optionally of a natriuretic peptide in a sample selected from the group consisting of blood, serum and plasma from the human subject, and b) comparing the amount of ESM-1 and optionally of the natriuretic peptide to a reference amount, wherein an amount of ESM-1 in the sample which is increased as compared to the reference amount is indicative for the subject being at risk of recurrence of atrial fibrillation; and c) administering to said human subject identified as at risk of atrial fibrillation at least one anticoagulant and/or an increased dosage of an already administered anticoagulant.

2 . The method of claim 1 , wherein the subject is suspected to suffer from atrial fibrillation, and wherein the assessment of atrial fibrillation is the diagnosis of atrial fibrillation.

3 . The method of claim 2 , wherein an amount of ESM-1 in the sample from a subject which is increased as compared to the reference amount is indicative for a subject suffering from atrial fibrillation.

4 . The method of claim 1 , wherein the amounts of ESM-1 and a natriuretic peptide are determined in step a), and wherein the method comprises the further steps of c) calculating a ratio of the amount of the natriuretic peptide as determined in step a) to the amount of ESM-1 as determined in step a), and comparing said calculated ratio to a reference ratio.

5 . The method of claim 4 , wherein a ratio which is decreased as compared to the reference ratio, is further indicative for a subject who suffers from atrial fibrillation.

6 . The method of claim 1 , wherein the subject is suffering from atrial fibrillation, and wherein the assessment of atrial fibrillation is the differentiation between paroxysmal and persistent atrial fibrillation, wherein an amount of ESM-1 in the sample from a subject which is increased as compared to the reference amount is indicative for a subject suffering from persistent atrial fibrillation and/or wherein an amount of ESM-1 in the sample from a subject which is decreased as compared to the reference amount is indicative for a subject suffering from paroxysmal atrial fibrillation.

7 . The method of claim 1 , wherein the assessment of atrial fibrillation is the identification of a subject who shall be subjected to electrocardiogra (ECG).

8 . The method of claim 1 , wherein the subject suffers from atrial fibrillation and wherein the assessment of atrial fibrillation is the assessment of a therapy for atrial fibrillation.

9 . The method of claim 1 , wherein the human subject with documented atrial fibrillation is on anticoagulation therapy.

10 . The method of claim 1 , wherein the anticoagulant is selected from the group consisting of heparin, a coumarin derivative, tissue factor pathway inhibitor (TFPI), antithrombin III, factor IXa inhibitors, factor Xa inhibitors, inhibitors of factors Va and VIIIa and thrombin inhibitors.

11 . The method of claim 1 , wherein the human subject suffering from atrial fibrillation is identified as at risk of an adverse event associated with atrial fibrillation within a period of 1 to 10 years.

Assignees

• Roche Diagnostics Operations Inc
• Maastricht Univ Medical Center
• Univ Maastricht
• Acad Ziekenhuis Maastricht

Inventors

• Karl Johann
• Kastner Peter
• Latini Roberto
• Masson Serge
• Wienhues-Thelen Ursula-Henrike
• Ziegler Andre
• Dietrich Manuel
• Schotten Ulrich
• Rolny Vinzent

Classifications

• A61B5/318

  Heart-related electrical modalities, e.g. electrocardiography [ECG] · CPC title

• G01N2333/4712

  Muscle proteins, e.g. myosin, actin, protein · CPC title

• G01N2800/325

  Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure · CPC title

• G01N2800/326

  Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes · CPC title

• G01N2800/2871

  Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event · CPC title